Oppenheimer Holdings Inc. reissued their outperform rating on shares of Syros Pharmaceuticals Inc (NASDAQ:SYRS) in a report released on Wednesday. The brokerage currently has a $28.00 price target on the stock.
A number of other equities research analysts also recently weighed in on the company. Cann reiterated a buy rating and issued a $28.00 target price on shares of Syros Pharmaceuticals in a report on Tuesday, February 21st. Zacks Investment Research upgraded Syros Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, February 8th. Finally, Wedbush reiterated an outperform rating and issued a $18.00 target price (down from $22.00) on shares of Syros Pharmaceuticals in a report on Monday, March 20th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $20.29.
Syros Pharmaceuticals (NASDAQ:SYRS) traded up 2.57% during midday trading on Wednesday, hitting $14.79. The stock had a trading volume of 9,088 shares. Syros Pharmaceuticals has a 1-year low of $8.16 and a 1-year high of $21.50. The stock’s 50-day moving average is $13.62 and its 200-day moving average is $13.24. The stock’s market capitalization is $345.97 million.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Monday, March 20th. The company reported ($0.47) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.64) by $0.17. On average, equities research analysts anticipate that Syros Pharmaceuticals will post ($3.02) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was originally posted by sleekmoney and is the property of of sleekmoney. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://sleekmoney.com/syros-pharmaceuticals-inc-syrs-receives-outperform-rating-from-oppenheimer-holdings-inc/1739104.html.
Large investors have recently modified their holdings of the company. Baker BROS. Advisors LP purchased a new stake in Syros Pharmaceuticals during the third quarter valued at approximately $2,836,000. JPMorgan Chase & Co. purchased a new stake in Syros Pharmaceuticals during the third quarter valued at approximately $1,892,000. AWM Investment Company Inc. purchased a new stake in Syros Pharmaceuticals during the third quarter valued at approximately $660,000. State Street Corp increased its stake in Syros Pharmaceuticals by 81.9% in the fourth quarter. State Street Corp now owns 45,447 shares of the company’s stock valued at $554,000 after buying an additional 20,468 shares in the last quarter. Finally, Spark Investment Management LLC purchased a new stake in Syros Pharmaceuticals during the third quarter valued at approximately $160,000. Institutional investors and hedge funds own 54.47% of the company’s stock.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/syros-pharmaceuticals-inc-syrs-receives-outperform-rating-from-oppenheimer-holdings-inc/1739104.html
Receive News & Ratings for Syros Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.